Occult hypoperfusion and mortality in patients with suspected infection

Harvard University, Cambridge, Massachusetts, United States
Intensive Care Medicine (Impact Factor: 5.54). 12/2007; 33(11):1892-9. DOI: 10.1007/s00134-007-0680-5
Source: PubMed

ABSTRACT To determine, in the early stages of suspected clinically significant infection, the independent relationship of the presenting venous lactate level to 28-day in-hospital mortality.
Prospective, observational cohort study.
Urban, university tertiary-care hospital.
One thousand two hundred and eighty seven adults admitted through the emergency department who had clinically suspected infection and a lactate measurement.
Seventy-three [5.7% (95% CI 4.4-6.9%)] patients died in the hospital within 28 days. Lactate level was strongly associated with 28-day in-hospital mortality in univariate analysis (p<0.0001). When stratified by blood pressure, lactate remained associated with mortality (p<0.0001). Normotensive patients with a lactate level >or=4.0 mmol/l had a mortality rate of 15.0% (6.0-24%). Patients with either septic shock or lactate >or=4.0 mmol/l had a mortality rate of 28.3% (21.3-35.3%), which was significantly higher than those who had neither [mortality of 2.5% (1.6-3.4%), p<0.0001. In a model controlling for age, blood pressure, malignancy, platelet count, and blood urea nitrogen level, lactate remained strongly associated with mortality. Patients with a lactate level of 2.5-4.0 mmol/l had adjusted odds of death of 2.2 (1.1-4.2); those with lactate >or=4.0 mmol/l had 7.1 (3.6-13.9) times the odds of death. The model had good discrimination (AUC=0.87) and was well calibrated.
In patients admitted with clinically suspected infection, the venous lactate level predicts 28-day in-hospital mortality independent of blood pressure and adds significant prognostic information to that provided by other clinical predictors.

Download full-text


Available from: Nathan I Shapiro, Jul 01, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The evidence for prognostication using lactate is often based on arterial lactate (AL). Arterial sampling is painful and difficult, and carries risks. Studies comparing peripheral venous lactate (PVL) with AL showed little difference but predominantly included patients with normal lactate. The objective of this study was to measure agreement between PVL and AL in patients with elevated venous lactate. This is a retrospective cross-sectional study. Inclusion criteria: ED patients age ≥16, attending from October 2010 to June 2011 inclusive, with PVL ≥2.0mmol/L and AL taken within 1 hour. Exclusion criteria: intravenous fluid prior to or between initial venous and arterial sampling. Primary endpoint: agreement between PVL and AL defined as mean difference ±95% limits of agreement (LOA). The misclassification rate was assessed. N=232. VL median 3.50mmol/L, range 2.00 to 15.00mmol/L. AL median 2.45mmol/L, range 1.0 to 13.2mmol/L. The mean difference±SD between PVL and AL for all patients was 1.06±1.30mmol/L (95%LOA -1.53 to 3.66mmol/L). Using a cut-off of 2mmol/L and 4mmol/L, 36.2% and 17.9% of patients respectively were incorrectly classified as having elevated lactate. We report greater bias between VL and AL with broader LOA than previously documented. This may partly be due to the fact that we studied only patients with abnormal venous values, for whom close agreement would confer greatest clinical significance. The agreement between abnormal PVL and AL is poor and the high rate of misclassification may suggest that PVL is not a good substitute for AL if the venous lactate is abnormal.
    The American journal of emergency medicine 03/2014; 32(6). DOI:10.1016/j.ajem.2014.03.007 · 1.15 Impact Factor
  • Source
    Sepsis - An Ongoing and Significant Challenge, 1 10/2012: chapter 6: pages 133-156; InTech., ISBN: 978-953-51-0780-4
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: The objective of this study is to determine if metformin use affects the prevalence and prognostic value of hyperlactatemia to predict mortality in septic adult emergency department (ED) patients. METHODS: This is a single-center retrospective cohort study. Emergency department providers identified study subjects; data were collected from the medical record. PATIENTS: Adult ED patients with suspected infection and 2 or more systemic inflammatory response syndrome criteria were included. The outcome was 28-day mortality. The primary risk variable was serum lactate (<2.0, 2.0-3.9, ≥4.0 mmol/L) categorized by metformin use; covariates: demographics, Predisposition, Infection, Response, Organ Dysfunction score and metformin use contraindications. SETTING: The study was conducted at an urban teaching hospital; February 1, 2007 to October 31, 2008. RESULTS: A total of 1947 ED patients were enrolled; 192 (10%) were taking metformin; 305 (16%) died within 28 days. Metformin users had higher median lactate levels than nonusers (2.2 mmol/L [interquartile range, 1.6-3.2] vs 1.9 mmol/L [interquartile range, 1.3-2.8]) and a higher, although nonsignificant, prevalence of hyperlactatemia (lactate ≥4.0 mmol/L) (17% vs 13%) (P = .17). In multivariate analysis (reference group nonmetformin users, lactate <2.0 mmol/L), hyperlactatemia was associated with an increased adjusted 28-day mortality risk among nonmetformin users (odds ratio [OR], 3.18; P < .01) but not among metformin users (OR, 0.54; P = .33). In addition, nonmetformin users had a higher adjusted mortality risk than metformin users (OR, 2.49; P < .01). These differences remained significant when only diabetic patients were analyzed. CONCLUSIONS: In this study of adult ED patients with suspected sepsis, metformin users had slightly higher median lactate levels and prevalence of hyperlactatemia. However, hyperlactatemia did not predict an increased mortality risk in patients taking metformin.
    The American journal of emergency medicine 03/2012; 30(9). DOI:10.1016/j.ajem.2012.01.014 · 1.15 Impact Factor